Pfizer Recalls All Lots of Chantix Due to Potential Carcinogen
FRIDAY, Sept. 17, 2021 (HealthDay News) -- Pfizer is expanding the recall of its antismoking drug Chantix (varenicline), the company announced Friday.
The nationwide recall of all Chantix 0.5-mg and 1-mg tablets was prompted because they may contain levels of a nitrosamine, N-nitroso-varenicline, that are at or above levels approved by the U.S. Food and Drug Administration.
Long-term ingestion of N-nitroso-varenicline may be linked to a "theoretical potential increased cancer risk in humans," the company said, adding that no immediate risk to patients taking Chantix exists.
"The health benefits of stopping smoking outweigh the theoretical potential cancer risk from the nitrosamine impurity in varenicline," Pfizer said in its statement.
So far, Pfizer has received no reports of adverse events tied to this recall, the company stated.
Related Posts
Need for Organ Transplants Surges at Big Motorcycle Rallies: Study
TUESDAY, Nov. 29, 2022 (HealthDay News) -- Once a year, giant motorcycle rallies...
Former College Football Players Suffer More Brain Disorders as They Age
THURSDAY, April 21, 2022 (HealthDay News) -- College football players live...
FDA Approves First Gene Therapy to Treat Duchenne Muscular Dystrophy
FRIDAY, June 23, 2023 (HealthDay News) -- The U.S. Food and Drug Administration...
El cambio climático empeora incluso más a 218 enfermedades infecciosas
MARTES, 9 de agosto de 2022 (HealthDay News) -- Las inundaciones, las olas de...